美立蝕®,姜黄素-磷脂复合物的产品评估登记,用于骨关节炎的补充管理。

Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis.

机构信息

Irvine3 Labs, Department of Biomedical Sciences, Chieti-Pescara University, Pescara, Italy.

出版信息

Panminerva Med. 2010 Jun;52(2 Suppl 1):55-62.

PMID:20657536

Abstract

AIM

A proprietary complex of curcumin with soy phosphatidylcholine (Meriva®, Indena SpA) was evaluated in a registry study to define its efficacy in 50 patients with osteoarthritis (OA) at dosages corresponding to 200 mg curcumin per diem.

METHODS

OA signs/symptoms were evaluated by the WOMAC scores. Mobility was studied by walking performance (treadmill), and inflammatory status was assessed by measurements of C-reactive protein (CRP).

RESULTS

After three months of treatment, the global WOMAC score decreased by 58% (P<0.05), walking distance in the treadmill test was prolonged from 76 m to 332 m (P<0.05), and CRP levels decreased from 168 +/- 18 to 11.3 +/-. 4.1 mg/L in the subpopulation with high CRP. In comparison, the control group experienced only a modest improvement in these parameters (2% in the WOMAC score, from 82 m to 129 m in the treadmill test, and from 175 +/- 12.3 to 112 +/- 22.2 mg/L in the CRP plasma concentration), while the treatment costs (use of anti-inflammatory drugs, treatment and hospitalization) were reduced significantly in the treatment group.

CONCLUSION

These results show that Meriva® is clinically effective in the management and treatment of osteoarthritis and suggest that the increased stability and better absorption of curcumin induced by complexation with phospholipids have clinical relevance, setting the stage for larger and more prolonged studies.

摘要

目的

姜黄素与大豆磷脂复合物（Meriva ® ，Indena SpA）的专有复合物在注册研究中进行了评估，以确定其在 50 名骨关节炎（OA）患者中的疗效，剂量相当于每日 200 毫克姜黄素。

方法

通过 WOMAC 评分评估 OA 体征/症状。通过跑步机行走性能研究运动能力，通过测量 C 反应蛋白（CRP）评估炎症状态。

结果

治疗三个月后，全球 WOMAC 评分下降 58%（P<0.05），跑步机测试中的步行距离从 76m 延长至 332m（P<0.05），CRP 水平从 168 +/- 18 降至 11.3 +/-. 4.1mg/L 在 CRP 水平较高的亚组中。相比之下，对照组在这些参数上仅略有改善（WOMAC 评分中为 2%，从 82m 增加到 129m 跑步机测试，从 175 +/- 12.3 降至 112 +/- 22.2mg/L CRP 血浆浓度），而治疗组的治疗费用（使用抗炎药、治疗和住院）显著降低。